Morgan Stanley, Cowen, RBC to be bookrunners; Oppenheimer assists
By Devika Patel
Knoxville, Tenn., July 25 – Ocular Therapeutix, Inc. said it priced its $65 million initial public offering of stock with a $9.75 million greenshoe. The deal was announced June 20.
The company will sell 5 million common shares at $13.00 apiece.
Morgan Stanley & Co. LLC, Cowen and Co. and RBC Capital Markets are the joint bookrunning managers.
Proceeds will be used for clinical trials, research and development, sales and marketing, expanding manufacturing capacity, working capital and other general corporate purposes.
The biopharmaceutical company is based in Bedford, Mass. The company intends to list its common stock on the Nasdaq under the symbol “OCUL.”
| Issuer: | Ocular Therapeutix, Inc.
|
| Issue: | Common stock
|
| Amount: | $65 million
|
| Greenshoe: | $9.75 million
|
| Shares: | 5 million
|
| Price: | $13.00
|
| Warrants: | No
|
| Bookrunners: | Morgan Stanley & Co. LLC, Cowen and Co. and RBC Capital Markets
|
| Co-manager: | Oppenheimer & Co.
|
| Announcement date: | June 20
|
| Pricing date: | July 25
|
| Stock exchange: | Nasdaq: OCUL
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
